- 12-week healing rate increased by approx. 30%, costs reduced by 27%
- To be expanded to insurance negotiations in Germany, France, Italy, and beyond

ROKIT Healthcare (KOSDAQ: 376900, CEO Seokhwan You), a company specializing in AI-driven hyper-personalized organ regeneration platforms, has secured official grounds for Pharmacoeconomics (economic evaluation of pharmaceuticals), a key basis for insurance listing in the UK and Europe.

Accordingly, the company plans to submit an insurance application to the UK’s NICE (National Institute for Health and Care Excellence), with UK insurance coverage likely to be obtained in the first half of next year. This is evaluated as a signal for full-scale entry into the European market, following the approval from the UK MHRA (Medicines and Healthcare products Regulatory Agency) in June of last year.

According to the pharmacoeconomic analysis, the 12-week complete healing rate for patients with chronic diabetic foot ulcers showed a significant advantage at 96.2% when using ROKIT Healthcare’s technology, compared to 68.5% when using conventional Skin Substitutes (SDS). Furthermore, when calculating lifetime medical costs from the perspective of the UK NHS (National Health Service), the use of ROKIT Healthcare’s technology resulted in a 27% cost reduction per patient, saving approximately 40 million KRW.

Quality of Life indicators (QALY) also improved by 0.202, with ROKIT Healthcare scoring 8.392 compared to 8.190 for Negative Pressure Wound Therapy (NPWT). Consequently, the report classified ROKIT Healthcare’s technology as a ‘Dominant’ treatment (more effective and less expensive).

A ROKIT Healthcare official explained, “Our AI organ regeneration platform utilizes an AI-customized regeneration patch made from micronized autologous fat, applied in a single surgical procedure,” adding, “These results are the outcome of the platform inducing powerful skin regeneration and angiogenesis (blood vessel formation).”

This model is significant as it is a ‘Reference Model’ that reflects NHS treatment patterns and cost data in accordance with NICE standards, making it directly applicable to the UK insurance review process. It is also scheduled to be expanded and applied to future insurance negotiations in major EU nations such as Germany, France, and Italy.

“This is the first official document in Europe that proves economic feasibility alongside clinical data,” said the ROKIT Healthcare official. “By presenting the attractive options of ‘saving treatment costs and reducing amputation risks’ to European public insurance systems currently under budget pressure, we have laid the foundation to leap forward as a global leader.”